Dr. Reddy's To Submit Final Clinical Trial Data From Russia For Sputnik Light Approval
After the Indian drug regulator denied permission to conduct phase III study of single-dose Sputnik Light locally, Dr. Reddy's Laboratories Ltd. will submit results of the final clinical trial underway in Russia.
Dr. Reddy's had presented the interim safety and efficacy data from the phase I and II trials in Russia and a proposal to conduct the third phase in India, the company said in an exchange filing on Friday. The regulator's Subject Expert Committee said the safety, immunogenicity and efficacy results from the final trail in Russia would be needed to consider "marketing authorisation" of Sputnik Light in India.
The regulator on June 30 denied approval for conducting the final trial in India. This single-dose version of the Sputnik V, already approved for emergency use in India, was expected to speed up the pace of inoculation amid the looming threat of a third wave of Covid-19.
Since Sputnik Light is nothing but the first dose of Sputnik V, the committee said that trial has already been conducted in India, according to the filing, and there seems to be inadequate data and justification in conducting a separate similar study.
Related Coverage
-
India's Troika Of Good Luck | Joining The Dots
A weaker Trump, a cooling AI trade and resilient earnings have put Indian markets back in favour. Rising inflation could spoil the party.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
